# Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

> **NCT01273064** · PHASE2 · TERMINATED · sponsor: **Conatus Pharmaceuticals Inc.** · enrollment: 114 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** CTS-1027
- **DRUG:** pegylated interferon
- **DRUG:** Ribavirin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01273064
- **Lead sponsor:** Conatus Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2011-09
- **Final completion:** 2011-10
- **Target enrollment:** 114 (ACTUAL)
- **Why stopped:** Risk-benefit ratio
- **Last updated:** 2012-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01273064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01273064, "Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01273064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*